A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma von Jonasch, E., Hasanov, E., Corn, P.G., Moss, T., Shaw, K.R., Stovall, S., Marcott, V., Gan, B., Bird, S., Wang, X., Do, K.A., Altamirano, P.F., Zurita, A.J., Doyle, L.A., Lara, P.N., Tannir, N.M.

Volltext

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies von Matrana, M.R, Duran, C, Shetty, A, Xiao, L, Atkinson, B.J, Corn, P, Pagliaro, L.C, Millikan, R.E, Charnsangave, C, Jonasch, E, Tannir, N.M

Volltext

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma von Motzer, Robert J, Tannir, Nizar M, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Choueiri, Toni K, Plimack, Elizabeth R, Barthélémy, Philippe, Porta, Camillo, George, Saby, Powles, Thomas, Donskov, Frede, Neiman, Victoria, Kollmannsberger, Christian K, Salman, Pamela, Gurney, Howard, Hawkins, Robert, Ravaud, Alain, Grimm, Marc-Oliver, Bracarda, Sergio, Barrios, Carlos H, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I, Chen, Allen C, Mekan, Sabeen, McHenry, M. Brent, Wind-Rotolo, Megan, Doan, Justin, Sharma, Padmanee, Hammers, Hans J, Escudier, Bernard

Volltext

Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR) von Schmidinger, M, Motzer, R.J, Powles, T, Escudier, B, Tannir, N.M, Mainwaring, P.N, Rini, B.I, Hammers, H.J, Donscov, F, Roth, B, Peltola, K, Lee, J.L, Heng, D.Y.C, Aftab, D.T, Hessel, C, Scheffold, C, Schwab, G, Pal, S, Hutson, T.E, Choueiri, T.K

Volltext

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors von Shah, A.Y., Kotecha, R.R., Lemke, E.A., Chandramohan, A., Chaim, J.L., Msaouel, P., Xiao, L., Gao, J., Campbell, M.T., Zurita, A.J., Wang, J., Corn, P.G., Jonasch, E., Motzer, R.J., Sharma, P., Voss, M.H., Tannir, N.M.

Volltext

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis von Campbell, Matthew T., Bilen, Mehmet A., Shah, Amishi Y., Lemke, Emily, Jonasch, E., Venkatesan, A.M., Altinmakas, E., Duran, C., Msaouel, Pavlos, Tannir, N.M.

Volltext

High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma von Ho, T H, Park, I Y, Zhao, H, Tong, P, Champion, M D, Yan, H, Monzon, F A, Hoang, A, Tamboli, P, Parker, A S, Joseph, R W, Qiao, W, Dykema, K, Tannir, N M, Castle, E P, Nunez-Nateras, R, Teh, B T, Wang, J, Walker, C L, Hung, M-C, Jonasch, E

Volltext

Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis von Liu, X-D, Yao, J, Tripathi, D N, Ding, Z, Xu, Y, Sun, M, Zhang, J, Bai, S, German, P, Hoang, A, Zhou, L, Jonasch, D, Zhang, X, Conti, C J, Efstathiou, E, Tannir, N M, Eissa, N T, Mills, G B, Walker, C L, Jonasch, E

Volltext

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma von Zurita, A.J., Jonasch, E., Wang, X., Khajavi, M., Yan, S., Du, D.Z., Xu, L., Herynk, M.H., McKee, K.S., Tran, H.T., Logothetis, C.J., Tannir, N.M., Heymach, J.V.

Volltext

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III Ch... von Tannir, N.M., Albigès, L., McDermott, D.F., Burotto, M., Choueiri, T.K., Hammers, H.J., Barthélémy, P., Plimack, E.R., Porta, C., George, S., Donskov, F., Atkins, M.B., Gurney, H., Kollmannsberger, C.K., Grimm, M.-O., Barrios, C., Tomita, Y., Castellano, D., Grünwald, V., Rini, B.I., Jiang, R., Desilva, H., Fedorov, V., Lee, C.-W., Motzer, R.J.

Volltext

Pilot trial of sunitinib therapy in patients with von Hippel–Lindau disease von Jonasch, E., McCutcheon, I.E., Waguespack, S.G., Wen, S., Davis, D.W., Smith, L.A., Tannir, N.M., Gombos, D.S., Fuller, G.N., Matin, S.F.

Volltext

678P Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICI) von Hahn, A.W., Viscuse, P.V., Pieretti, A., Wiele, A.J., Jonasch, E., Gao, J., Zurita, A.J., Shah, A.Y., Campbell, M.T., Sharma, P., Wood, C.G., Tannir, N.M., Karam, J.A., Msaouel, P.

Volltext

661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) von Motzer, R.J., Tannir, N.M., McDermott, D.F., Burotto, M., Choueiri, T.K., Hammers, H.J., Plimack, E.R., Porta, C.G., George, S., Powles, T.B., Donskov, F., Gurney, H., Kollmannsberger, C.K., Grimm, M-O., Tomita, Y., Rini, B.I., McHenry, M.B., Lee, C-W., Escudier, B.

Volltext

83P Evaluation of concordance between PD-L1 immunohistochemistry 28-8 and 22C3 pharmDx assays in metastatic urothelial carcinoma (mUC) in PIVOT-10 von Siefker-Radtke, A.O., Hoch, U., Loriot, Y., Balar, A.V., Bilen, M.A., Tannir, N.M., Cho, D.C., Choudhury, A., Chien, D., Yu, D., Currie, S.L., Novotny, J., Santiago, L., Tagliaferri, M.A., Zalevsky, J., Huddart, R.A.

Volltext

P183 Nivolumab Plus Ipilimumab (NIVO+IPI) vs Sunitinib (SUN) for first-line treatment of advanced Renal Cell Carcinoma (aRCC): Efficacy across number of International Metastatic Re... von Escudier, B., Motzer, R.J., Tannir, N.M., Rini, B.I., Porta, C., Tomita, Y., Fedorov, V., Desilva, H., Jiang, R., Grünwald, V.

Volltext

Osseous Pseudoprogression in Vertebral Bodies Treated with Stereotactic Radiosurgery: A Secondary Analysis of Prospective Phase I/II Clinical Trials von Amini, B, Beaman, C B, Madewell, J E, Allen, P K, Rhines, L D, Tatsui, C E, Tannir, N M, Li, J, Brown, P D, Ghia, A J

Volltext

964P - Lenvatinib (Len) alone or in combination with everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhib... von Wiele, A.J., Ross, J., Chahoud, J., Lim, Z., Xiao, L., Campbell, M.T., Shah, A.Y., Zurita Saavedra, A., Jonasch, E., Tannir, N.M.

Volltext

Lenvatinib (Len) alone or in combination with everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (... von Wiele, A.J., Ross, J., Chahoud, J., Lim, Z., Xiao, L., Campbell, M.T., Shah, A.Y., Zurita Saavedra, A., Jonasch, E., Tannir, N.M.

Volltext

Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214 von Grünwald, V., Choueiri, T.K., Rini, B.I., Powles, T., George, S., Grimm, M.-O., McHenry, M.B., Maurer, M., Motzer, R.J., Hammers, H.J., Tannir, N.M., Albiges, L.

Volltext

950P - Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214 von Grünwald, V., Choueiri, T.K., Rini, B.I., Powles, T., George, S., Grimm, M.-O., McHenry, M.B., Maurer, M., Motzer, R.J., Hammers, H.J., Tannir, N.M., Albiges, L.

Volltext